Salubris Biotherapeutics

Focus: Salubris Biotherapeutics is an early-stage biologics company focused on cardiovascular and oncology therapeutics headquartered in Gaithersburg, Maryland. The company operates in the pre-revenue biotech space with a pipeline of Phase 1/2 candidates.

Cardiovascular Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Salubris Biotherapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Salubris Biotherapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

JK07

Heart Failure With Reduced Ejection Fraction

Phase 1

Clinical Trials (1)

NCT04210375Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)

Phase 1

Help build intelligence for Salubris Biotherapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a focused biotech with active clinical programs in high-value therapeutic areas (cardiovascular and oncology)
Potential to build specialized expertise on JK-series candidates across heart failure and solid tumor indications
Early-stage environment offers visibility into drug development and potentially faster career progression

Watch Out For

Zero active job openings reported and minimal public visibility suggest limited near-term hiring or nascent organizational structure
Pipeline consists entirely of Phase 1/2 programs with no Phase 3 data, indicating significant technical and regulatory risk before any meaningful revenue generation
Lack of disclosed funding, financials, and employee count raises questions about capitalization, burn rate, and runway stability

Generated by Claude from Salubris Biotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

JK07

Heart Failure With Preserved Ejection Fraction

Phase 1

Clinical Trials (1)

NCT05322616Single-Ascending Dose Study of JK07 in Subjects With HFpEF

Phase 1

JK06

Solid Tumor

Phase 1/2

Clinical Trials (1)

NCT06667960Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer

Phase 1/2